Alex Zhavoronkov

Alex Zhavoronkov founded Insilico Medicine and developed one of the first end-to-end AI drug discovery platforms, using generative adversarial networks and reinforcement learning to design novel drug molecules with desired pharmacological properties for cancer and aging-related diseases. His platform PandaOmics uses multi-omics data analysis with AI to identify novel drug targets, while Chemistry42 generates optimized molecular structures targeting them. His company achieved a landmark by advancing an AI-discovered drug candidate for cancer (targeting CDK8/CDK19) into clinical trials in under 18 months and at a fraction of traditional costs. He has demonstrated that AI can compress the drug discovery timeline from target identification through lead optimization for oncology programs.